Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genasense User Fee Date For CLL Extended Following New Data Submission

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has extended the action date for Genta's oblimersen 90 days.

You may also be interested in...



Genta Will Appeal FDA “Not Approvable” Action On Genasense

Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.

Genta Will Appeal FDA “Not Approvable” Action On Genasense

Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.

Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense

Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.

Related Content

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel